OM
EWTX icon

Opaleye Management’s Edgewise Therapeutics EWTX Stock Holding History

Opaleye Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Hold
500,000
– – 2.07% 16
2025
Q4 		$12.4M Hold
500,000
– – 1.64% 18
2025
Q3 		$8.11M Buy
500,000
+10,000
+2% +$142K 1.15% 20
2025
Q2 		$6.42M Buy
490,000
+95,000
+24% +$1.37M 1.3% 17
2025
Q1 		$8.69M Sell
395,000
-85,000
-18% -$2.23M 1.93% 11
2024
Q4 		$12.8M Sell
480,000
-42,500
-8% -$1.35M 2.24% 10
2024
Q3 		$13.9M Sell
522,500
-57,500
-10% -$1.14M 2.33% 11
2024
Q2 		$10.4M Sell
580,000
-85,000
-13% -$1.48M 2.39% 10
2024
Q1 		$12.1M Sell
665,000
-34,000
-5% -$540K 2.64% 10
2023
Q4 		$7.65M Sell
699,000
-176,405
-20% -$1.24M 2.03% 14
2023
Q3 		$5.02M Buy
875,405
+60,405
+7% +$411K 1.63% 14
2023
Q2 		$6.32M Buy
815,000
+65,000
+9% +$548K 1.51% 17
2023
Q1 		$5M Buy
750,000
+138,600
+23% +$1.28M 1.5% 22
2022
Q4 		$5.47M Sell
611,400
-23,600
-4% -$221K 1.9% 16
2022
Q3 		$6.25M Buy
635,000
+183,600
+41% +$1.86M 2.58% 12
2022
Q2 		$3.59M Buy
451,400
+148,400
+49% +$1.12M 1.62% 20
2022
Q1 		$2.94M Buy
+303,000
New +$3.9M 0.91% 30

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management's EWTX Position: Q1 2026 in Review

Opaleye Management held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 500,000 shares worth $15.8M. The position accounts for 2.07% of the portfolio, ranked #16.

Opaleye Management first reported a position in EWTX in Q1 2022 and has held it in 17 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Opaleye Management held 500,000 shares of Edgewise Therapeutics worth $15.8M as of Q1 2026.
  • Opaleye Management left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up 2.07% of Opaleye Management's portfolio in Q1 2026, its #16 holding.
  • Opaleye Management first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.